Drug Profile
Linifanib
Alternative Names: A-741439; ABT-869; RG-3635Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie
- Class Antineoplastics; Indazoles; Phenylurea compounds; Small molecules; Urea compounds
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Liver cancer; Non-small cell lung cancer; Renal cancer